Loading clinical trials...
Loading clinical trials...
A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Solid Tumors
Conditions
Interventions
EGFRBi-armed autologous activated T cells
Locations
1
United States
Roger Willaims Medical Center
Providence, Rhode Island, United States
Start Date
October 1, 2009
Primary Completion Date
December 1, 2014
Completion Date
February 1, 2015
Last Updated
March 25, 2015
NCT01247597
NCT06898450
NCT00026884
NCT07169851
NCT07213804
NCT07159659
Lead Sponsor
Roger Williams Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions